Thymosin Alpha 1 Explored for Early Lung Cancer Immunomodulation Post-Surgery
Background
Patients with Stage I Non-Small Cell Lung Cancer (NSCLC) often undergo surgical resection, but recurrence remains a significant concern, partly due to residual circulating tumor cells (CTCs) and immunosenescence (age-related decline in immune function). Immunomodulatory therapies hold promise for improving outcomes by bolstering the body's natural defenses. This study specifically addresses the potential of Thymosin Alpha 1 (Tα1) to reduce CTCs and improve immune profiles in early-stage NSCLC patients after surgery.
Results
As a recruiting study, specific results are not yet available, but the researchers aim to determine if Thymosin Alpha 1 (Tα1) treatment can significantly impact key markers of disease recurrence and immune health. The primary outcome is to measure the number of circulating tumor cells (CTCs) in peripheral blood 4 months after surgery, expecting a reduction in the Tα1 group. Secondary outcomes include assessing the number of immune cells and their profile in peripheral blood, also 4 months after surgery, alongside monitoring adverse events within the same timeframe. The central hypothesis is that Tα1 treatment will lead to a measurable decrease in circulating tumor cells (CTCs) and an improvement in the immune cell profile compared to observation alone, potentially reducing recurrence risk.
Why It Matters
If successful, this study could demonstrate a novel adjuvant strategy to improve outcomes for patients with early-stage Non-Small Cell Lung Cancer (NSCLC). By targeting circulating tumor cells (CTCs) and immunosenescence, Thymosin Alpha 1 (Tα1) could offer a new approach to prevent recurrence after surgery. This research could establish Tα1 as a valuable immunomodulatory therapy in the clinical management of early NSCLC. Positive findings would pave the way for larger Phase II and III human trials, potentially leading to Tα1's integration into standard care protocols.